Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mazer

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|May 23, 2020
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or bothA Mazer Zumaeta, A Wright, A Syngelaki, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2000
Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virusM Javanbakht, A B Singh, N A Mazer, et al.
Neuron|February 16, 2010
Synaptic and network mechanisms of sparse and reliable visual cortical activity during nonclassical receptive field stimulationBilal Haider, Matthew R Krause, Alvaro Duque, et al.
Molecular Pharmaceutics|May 9, 2018
Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic ModelLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Molecular Pharmaceutics|January 5, 2016
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular DegenerationLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Molecular Pharmaceutics|June 21, 2017
Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic ModelLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Archives of Internal Medicine|July 27, 2011
Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalentNina P Paynter, Norman A Mazer, Aruna D Pradhan, et al.
Transplantation Proceedings|February 1, 1990
Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantationY Kang, M A Mazer, A M DeWolf, et al.
Clinical Endocrinology|March 14, 1998
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal menS Arver, A S Dobs, A W Meikle, et al.
Journal of Clinical Pharmacology|August 1, 1996
Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of doseD R Brocks, A W Meikle, S C Boike, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|May 23, 2020
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or bothA Mazer Zumaeta, A Wright, A Syngelaki, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2000
Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virusM Javanbakht, A B Singh, N A Mazer, et al.
Neuron|February 16, 2010
Synaptic and network mechanisms of sparse and reliable visual cortical activity during nonclassical receptive field stimulationBilal Haider, Matthew R Krause, Alvaro Duque, et al.
Molecular Pharmaceutics|May 9, 2018
Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic ModelLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Molecular Pharmaceutics|January 5, 2016
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular DegenerationLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Molecular Pharmaceutics|June 21, 2017
Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic ModelLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Archives of Internal Medicine|July 27, 2011
Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalentNina P Paynter, Norman A Mazer, Aruna D Pradhan, et al.
Transplantation Proceedings|February 1, 1990
Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantationY Kang, M A Mazer, A M DeWolf, et al.
Clinical Endocrinology|March 14, 1998
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal menS Arver, A S Dobs, A W Meikle, et al.
Journal of Clinical Pharmacology|August 1, 1996
Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of doseD R Brocks, A W Meikle, S C Boike, et al.
Pageof 15